Intrinsic Value of S&P & Nasdaq Contact Us

Surrozen, Inc. SRZNW NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
46/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Surrozen, Inc. (SRZNW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.

Analysts estimate Earnings Per Share (EPS) of $-14.94 and revenue of $0.01B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-21.67 vs est $-14.94 (missed -45%). 2025: actual $-32.37 vs est $-8.76 (missed -269.4%). Analyst accuracy: 48%.

EPS Estimates — SRZNW

48%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$21.67 vs Est –$14.94 ▼ 31.1% off
2025 Actual –$32.37 vs Est –$8.76 ▼ 72.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — SRZNW

80%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.011B vs Est $0.010B ▲ 6.1% off
2025 Actual $0.003B vs Est $0.002B ▲ 34.0% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message